Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 9/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402022 | 0.82 | ATR (0.46) | RIPK3PIK3C3CDK9GSK3BIRAK4 | |
| SCHEMBL2029613 | 0.82 | ATR (0.46) | RIPK3PIK3C3CDK9GSK3BIRAK4 | |
| SCHEMBL1094734 | 0.81 | TOP2A (0.44) | PIK3C3TOP2ACDK9CDK1CDK2 | |
| SCHEMBL5353074 | 0.79 | RIPK3 (0.45) | RIPK3GSK3B | |
| SCHEMBL17971420 | 0.78 | PIK3C3 (0.48) | PIK3C3CDK9GSK3AGSK3BAAK1 | |
| SCHEMBL5812808 | 0.78 | RIPK3 (0.41) | RIPK3PIK3C3CDK9CDK1CDK2 | |
| SCHEMBL13826405 | 0.78 | MAPK14 (0.51) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL10129965 | 0.77 | PIK3C3 (0.43) | PIK3C3AAK1IRAK4TGFBR1 | |
| SCHEMBL5349670 | 0.77 | CDK9 (0.42) | RIPK3PIK3C3TOP2ACDK9GSK3B | |
| SCHEMBL5251219 | 0.76 | EGFR (0.57) | PIK3C3GSK3BAAK1IRAK4TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| CN-102348697-B | Sulfonamide derivatives | PFIZER LTD | 2014-12-10 | — | — | CN | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| CN-102348697-A | Sulfonamide derivatives | PFIZER LTD | 2012-02-08 | — | — | CN | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | RIPK3 3750/4885PIK3C3 3536/4885TOP2A 2227/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | RIPK3 3750/4885PIK3C3 3536/4885TOP2A 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.